• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Proveris Scientific
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Favorex to market Marinomed’s Carragelose nasal spray in Thailand, Malaysia, Myanmar, and the Philippines

Marinomed Biotech announced that DKSH subsidiary Favorex has acquired commercialization rights to Marinomed’s Carragelose iota-carrageenan nasal spray for Thailand, Malaysia, Myanmar, and the Philippines. Earlier this year, Carragelose nasal spray was approved in Mexico, where it will be marketed as “Barlo” by M8. Perrigo markets the nasal spray in a number of European countries as “Physiomer Virus Defense.” The product is currently marketed in a total of 27 countries under a variety of brand names.

The company also announced that it has been granted a patent covering the use of carrageenans for the prevention and treatment of SARS-CoV-2 infection by the European Patent Office. In November 2020, Marinomed announced the initiation of a Phase 4 trial of the nasal spray agains viral respiratory infections, including COVID-19, and in March 2021, the company said that it was initiating a study of Inhaleen Carragelose iota-carageenan inhalation solution for the treatment of moderate COVID-19.

Marinomed CEO Andreas Grassauer commented, “In 2023, we could already report many good news for our Carragelose business, including the introduction of the allergen-blocking nasal spray and the moisturizing eye drops. Ending the year with a new partnership, a European patent and a successful manufacturing process shows once more that Carragelose is a success story.”

Read the Marinomed press release.

Share

published on December 15, 2023

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Merxin We Make Inhalers banner
    © 2025 OINDPnews